An update from Centessa Pharmaceuticals ( (CNTA) ) is now available.
Centessa Pharmaceuticals plc recently shared promising results from their Phase 1 trial of ORX750, an innovative drug designed to combat sleep deprivation. This novel orexin receptor 2 agonist significantly improved wakefulness in sleep-deprived volunteers, demonstrating both efficacy and safety, with no severe adverse events noted. With a favorable pharmacokinetic profile supporting once-daily dosing, the company is now poised to expedite Phase 2 trials, targeting conditions like narcolepsy and idiopathic hypersomnia. These findings could potentially revolutionize the treatment landscape for sleep-wake disorders.
For a thorough assessment of CNTA stock, go to TipRanks’ Stock Analysis page.
